ACE2 and COVID-19: ApoE4 reduces ACE2 expression and then imbalances the RAS system to more Ang II and less Ang 1–7 to increase inflammation, which has been reported to be a proposed mechanism for the ApoE genotype impacts COVID-19 outcomes [15].